Page 75 - Sohini Das

Cipla's Q1 PAT grows 24% to Rs 715 crore riding on domestic sales

The company posted a 27% YoY increase in income from operations, at Rs 5,504 cr. Ebitda grew 28% to Rs 1,346 cr with a resulting Ebitda margin of 24.5%

India may soon have Covid-19 vaccines for children. All you need to know

Zydus Cadila DNA-plasmid vaccine is the prime contender. It has held trials on children aged 12 years and above

Gennova to use mRNA tech to develop vaccines for Zika, tuberculosis

mRNA vaccines typically have stringent temperature requirements to remain stable

USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug

Analysts expect additional revenues of 8 to 15 per cent for Biocon, with no competition in sight

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

AstraZeneca finds small clot risk after first dose of Vaxzevria vaccine

No extra risk after second dose shows study led and funded by drug maker

DRL stock falls 10% after missing Q1 estimates, probe by US SEC

The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22

Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August

Trials on adolescents in Russia expected to end by October: DRL

Covid-19 vaccine for children likely in August: Health minister Mandaviya

Zydus Cadila has done trials on 12-plus; Bharat Biotech conducting trials on two-plus

Private sector to step up Covid-19 vaccination drive in towns, villages

Private hospitals see fall in demand for paid jabs after free vaccine announcement

Biocon likely to seek full marketing authorisation for Covid-19 drug

Expects results from phase 4 study of itolizumab by end of this quarter

No domestic vaccine maker has sought indemnity: Junior Health Minister

Bharti Pravin Pawar says Centre has set up team to deal with various issues related to procurement of Covid-19 vaccine from foreign firms

Air-pollution is major cause behind rising non-communicable diseases

Is the most prevalent risk factor among surveyed the population (76%), followed by low physical activity (67%), poor diet (55%). These three factors even beat stress, tobacco consumption, obesity

Prices of oral diabetes drugs set to fall as patents near expiry date

The diabetes segment has been growing faster than the country's overall drug market

Russia in talks with Kerala govt for Sputnik V plant, says state minister

Kerala State Industrial Development Corporation (KSIDC) to scout for land, prepare draft

Glenmark Lifesciences to double manufacturing capacity in five years

With formulation makers aiming at de-risk procurement by creating one more source for raw material other than China, the demand for APIs is rising, says company

Bharat Biotech had agreed to offer vaccine at reasonable rates to Govt: MoH

ICMR has spent Rs 35 cr on Covaxin clinical trials

What is the controversy surrounding Serum Institute's Covishield and EMA?

The vaccine did not make it to the European regulator's approved list, although it has been approved by WHO and also the UK MHRA

Serum Institute partners with RDIF to make 300 mn doses of Sputnik V

RDIF says SII can make combination doses of Astra-Sputnik in future

Oximeters, BP machines to get cheaper as NPPA caps trade margins at 70%

Earlier margins were as high as 709% for some devices; revised prices will come into effect from July 20